Clinical and Non‐clinical Evidence Supporting the Development of Masupirdine (SUVN‐502) for the Management of Agitation in Alzheimer’s Disease
The non-clinical and clinical data support further evaluation of Masupirdine for the management of agitation in AD. A global Phase-3, double-blind, randomized, placebo-controlled study to establish the efficacy, safety, tolerability, and pharmacokinetics of Masupirdine in patients with agitation in dementia of the Alzheimer's type (NCT05397639 and EudraCT 2021-003405-22) is in progress.
Authors
- Jyothsna Ravulu
- Vijay Benade
- Ramakrishna Nirogi (ORCID: https://orcid.org/0000-0002-2045-0784)
- Veera Raghava Chowdary Palacharla (ORCID: https://orcid.org/0000-0001-7493-4920)
- Abdul Rasheed Mohammed (ORCID: https://orcid.org/0000-0001-7873-4600)
- Anil Shinde
- Pradeep Jayarajan
- Satish Jetta
- Ramkumar Subramanian
- Renny Abraham
- Vinod Kumar Goyal
Institutions
- Suven Life Sciences (India) (IN)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_099716
- Primary Topic
- Neurotransmitter Receptor Influence on Behavior
- Type
- article
- Field-Weighted Citation Impact
- 0.00